Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
-
Published:2024-05-11
Issue:
Volume:
Page:
-
ISSN:0945-6317
-
Container-title:Virchows Archiv
-
language:en
-
Short-container-title:Virchows Arch
Author:
Davidson BenORCID, Holth Arild, Lindemann Kristina, Zahl Eriksson Ane Gerda, Nilsen Thale Andrea, Torgunrud Annette
Abstract
AbstractCarcinosarcoma (CS) is an uncommon and clinically aggressive malignancy. The objective of the present study was to characterize the molecular features of CS at various anatomic locations, including serous effusions. Specimens (n = 32) consisted of 25 biopsies/surgical resection specimens and 7 serous effusions (6 peritoneal, 1 pleural) from 25 patients. Fresh-frozen cell pellets and surgical specimens underwent targeted next-generation sequencing covering 50 unique genes. A total of 31 mutations were found in 25 of the 32 tumors studied, of which 1 had 3 mutations, 4 had 2 different mutations, and 20 had a single mutation. The most common mutations were in TP53 (n = 25 in 24 tumors; 1 tumor with 2 different mutations), with less common mutations found in RB1 (n = 2), MET (n = 1), KRAS (n = 1), PTEN (n = 1), and KIT (n = 1). Patient-matched specimens harbored the same TP53 mutation. Tumors with no detected mutations were more common in serous effusion specimens (3/7; 43%) compared with surgical specimens (4/25; 16%). In conclusion, the molecular landscape of CS is dominated by TP53 mutations, reinforcing the observation that the majority of these tumors develop from high-grade serous carcinoma. Whether CS cells in serous effusions differ from their counterparts in solid lesions remains uncertain.
Funder
University of Oslo
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. WHO Classification of Tumours Editorial Board. Female Genital Tumours (2020) WHO Classification of Tumours, 5th Edition, Volume 4. IARC, Lyon 2. Hollis RL, Croy I, Churchman M, Bartos C, Rye T, Gourley C, Herrington CS (2022) Ovarian carcinosarcoma is a distinct form of ovarian cancer with poorer survival compared to tubo-ovarian high-grade serous carcinoma. Br J Cancer 127(6):1034–1042. https://doi.org/10.1038/s41416-022-01874-8 3. Zhao S, Bellone S, Lopez S, Thakral D, Schwab C, English DP, Black J, Cocco E, Choi J, Zammataro L, Predolini F, Bonazzoli E, Bi M, Buza N, Hui P, Wong S, Abu-Khalaf M, Ravaggi A, Bignotti E, Bandiera E, Romani C, Todeschini P, Tassi R, Zanotti L, Odicino F, Pecorelli S, Donzelli C, Ardighieri L, Facchetti F, Falchetti M, Silasi DA, Ratner E, Azodi M, Schwartz PE, Mane S, Angioli R, Terranova C, Quick CM, Edraki B, Bilgüvar K, Lee M, Choi M, Stiegler AL, Boggon TJ, Schlessinger J, Lifton RP, Santin AD (2016) Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. Proc Natl Acad Sci USA 113(43):12238–12243. https://doi.org/10.1073/pnas.1614120113 4. Gotoh O, Sugiyama Y, Takazawa Y, Kato K, Tanaka N, Omatsu K, Takeshima N, Nomura H, Hasegawa K, Fujiwara K, Taki M, Matsumura N, Noda T, Mori S (2019) Clinically relevant molecular subtypes and genomic alteration-independent differentiation in gynecologic carcinosarcoma. Nat Commun 10(1):4965. https://doi.org/10.1038/s41467-019-12985-x 5. Brunetti M, Agostini A, Staurseth J, Davidson B, Heim S, Micci F (2019) Molecular characterization of carcinosarcomas arising in the uterus and ovaries. Oncotarget 10(38):3614–3624. https://doi.org/10.18632/oncotarget.26942
|
|